How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

279 results for

Hemorrhoid Coagulation

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Blood Flow Monitoring to Prevent Post-Polypectomy Induced Ulcer Bleeding

arm) with standard treatment using medical guidelines alone (controls) for prevention of delayed bleeding in high risk patients (on anti-coagulants or anti-platelet drugs or with large ulcers) after snare resection of benign colon polyps. Condition or disease Intervention/treatment Phase Delayed Post-Polypectomy Induced Ulcer Hemorrhage Device: Doppler Endoscopic Probe Not Applicable Detailed Description: Severe delayed post-polypectomy induced ulcer (PPIU) bleeding has become a much more common (...) problem with the increased numbers of colonoscopies being performed and with more patients taking anti-coagulants or anti-platelet drugs. Current medical guidelines may reduce bleeding during polypectomy, but are not effective for prevention of delayed bleeding. Empiric closure of PPIU's with clips is not effective because ulcers > 15 mm cannot be closed, does not treat the underlying artery in the ulcer base, and when the clips often fall off within 7 the underlying artery is exposed. As preliminary

2016 Clinical Trials

122. Safety and Effectiveness Evaluation of the ForConti Fecal Management System

neurological diagnosis Known life threatening disease such as cancer, immune deficiency state Significant cardiac arrhythmia Pregnant or Breastfeeding Inflammatory bowel disease Anti-coagulants and anti-platelets treatment, except Aspirin (low dose: 75-100 mg/day) Anorectal diseases: perianal abscess, active fistula, fissure, hemorrhoids grade 3 or 4, Pruritus ani or rectal bleeding Chronic pelvic pain Rectal surgery in past 6 months Contacts and Locations Go to Information from the National Library

2016 Clinical Trials

123. The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males

coagulation disorders (e.g. haemophilia, von Willebrand´s disease) Known disorders with increased bleeding risk (e.g. peridontosis, haemorrhoids, acute gastritis, peptic ulcer, intestinal ulcer) Known sensitivity to common causes of bleeding (e.g. nasal) History of thromboembolism History of occlusive vascular diseases History of vascular anomalies History of hypercholesterolemia History of myopathy Impaired liver function (AST, ALT, gGT, bilirubin > 3 x ULN) Impaired renal function (serum creatinine

2016 Clinical Trials

124. Efficacy and Safety of CLIFE1 Gel in Benign Anorectal Surgery

Viladecans Study Details Study Description Go to Brief Summary: Double-blinded multicenter randomized clinical trial to evaluate the efficacy and safety of CLIFE2 (lidocaine, referred as treatment A) respect CLIFE1 (lidocaine plus diclofenac, referred as treatment B) in benign anorectal surgery. Condition or disease Intervention/treatment Phase Fissure;Anal Fistula;Rectal Hemorrhoids Drug: anesthesics plus antiinflammatory, CLIFE1 Drug: local anesthesics, CLIFE2 Phase 4 Detailed Description: 120 patients (...) or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Patients undergoing benign anorectal surgery (out or inpatients), with the following diagnoses: anal fissure, fistula, hemorrhoids Use of subarachnoid anesthesia with lidocaine Exclusion Criteria

2016 Clinical Trials

125. Study of the Effects of Ethnicity on the Pharmacokinetics, Pharmacodynamics and Safety of DS-1040b

of major bleeding or major surgical procedure of any type within 6 months before Day 1. Subjects with any history of peptic ulcer, gastrointestinal bleeding including haematemesis, melena, or bleeding from haemorrhoids. Subjects with a history of minor bleeding episodes such as epistaxis, rectal bleeding (spots of blood on toilet paper), or gingival bleeding within 3 months before Day 1. Subjects who have any family history, suspected or documented, of coagulopathy or haemoglobinopathy or evidence (...) of abnormal coagulation parameters (eg, Prothrombin Time PT, International Normalised Ratio INR or Activated Partial Thromboplastin Time aPTT) at Screening. Subjects with borderline values for PT, INR or aPTT can be enrolled if the abnormality is considered not clinically significant by the investigator. Subjects with an estimated glomerular filtration rate (eGFR) at Screening using the MDRD (Modification of Diet in Renal Disease) equation < 90 mL/min. Likely possibility that the subject

2016 Clinical Trials

126. Motorized Spiral Colonoscopy Trial: A First Feasibility Trial

Colonoscopy Motorized Spiral Colonoscopy (MSC) with the novel motorized spiral endoscope represents a new technology which offers all of the advantageous options of spiral-assisted endoscopy with a faster and less invasive approach Procedure: Motorized Spiral Colonoscopy For any pathological finding during colonoscopy standard endoscopic techniques, e.g. forceps biopsy, injection, endoscopic mucosal resection, argon plasma coagulation Other Name: standard endoscopic interventions (not experimental (...) History of chronic inflammatory bowel disease Previously identified colorectal polyps/lesions with indication for endoscopic resection Any medical contraindication to standard colonoscopy Any prior abdominal surgery of the mid or lower gastrointestinal tract (except uncomplicated appendectomy) Known or suspected bowel obstruction or stenosis Known hemorrhoids 3rd degree Suspected perforation of the GI tract Inability to tolerate sedation for any reason Absence of a signed informed consent Contacts

2016 Clinical Trials

127. ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor

, stable lung function during the preceding three months and no acute upper or lower respiratory infection or pulmonary exacerbation during the preceding four weeks Hematology, serum chemistry, coagulation results at baseline with no clinically significant abnormalities that would interfere with the oral treatment with Orkambi® and with the study assessments, as judged by the investigator Able to understand and comply with protocol requirements, restrictions, and instructions and likely to complete (...) at baseline Advanced liver disease as documented by sonography Abnormal liver function at baseline, defined as ≥ 3 upper limit of normal in minimum 3 of the following: serum aspartate transaminase, serum alanine transaminase, gamma-glutamyl transpeptidase, or total bilirubin Abnormal blood creatine phosphokinase at baseline Abnormal renal function at baseline, defined as creatinine clearance < 60 mL/min Co-medication with strong CYP3A inhibitors and inducers Non-congenital lens opacities Haemorrhoids

2016 Clinical Trials

128. HDR Focal: Feasibility Study

lesions), on multiparametric MRI Prostate gland size <80cc Baseline IPSS <18 No TRUP within the past 6 months, nor large TURP defect Absence of radiological evidence of regional or distant metastases (optional evaluation, at physician discretion) No previous pelvic and/or prostate EBRT and/or brachytherapy No contraindications to general anesthesia, or spinal/epidural anesthesia Absence of bleeding diathesis and/or anti-coagulative therapy that cannot be temporarily ceased during brachytherapy (...) No contraindications to endorectal coil, surgically absent rectum, severe hemorrhoids or colorectal surgery Negative past medical history of Ulcerative Colitis, Crohn's Disease, Ataxia Telangiectasia, or SLE Absence of latex allergy No other medical conditions deemed by the PI to make patient ineligible for prostate HDR brachytherapy Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using

2016 Clinical Trials

129. Pilot Study to Describe Immune Responses of Healthy Women Following Immunization With Varicella Zoster Virus Vaccine

diabetes, gastrointestinal, cardiovascular, malignancy, neurological, psychiatric, metabolic, renal, hepatic, respiratory, auto-immune diseases, psoriasis, primary and acquired immunodeficiency status and rectal problems). Significant laboratory abnormalities, including coagulation (International Normalised Ratio- INR <1.0 or > 1.5). A positive pregnancy test or breast-feeding at screening; for the participants with reproductive potential, unwilling to use an effective method of preventing pregnancy (...) , suicidal attempt or ideation in the previous 3 years. Contra-indication for undergoing a biopsy due to bleeding diathesis, haemorrhoids, mucosal infection at the biopsy site, medication that interfere with clotting (e.g. warfarin or heparin) - both clinical and laboratory. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please

2015 Clinical Trials

130. Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions

& Development, LLC Information provided by (Responsible Party): Bayer Study Details Study Description Go to Brief Summary: Rivaroxaban is a substance developed for use in the treatment of blood coagulation disorders.Thrombosis (blood clots) can occur as a result of excessive coagulation activity in the blood vessels. Excessive coagulation activity can occur in children as well, and rivaroxaban is therefore being developed for the treatment of thromboembolic events in children and adolescents. As small (...) ) Sexes Eligible for Study: Male Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Healthy male subjects Age: 18 to 55 years (inclusive) at the first screening examination White Body Mass Index (BMI): ≥18.0 and ≤29.9 kg/m2 at the screening visit. Exclusion Criteria Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal Known coagulation disorders (e.g. von Willebrand's

2015 Clinical Trials

131. Bioequivalence Study of Rivaroxaban

be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal Subject with a history of relevant diseases of vital organs, of the central nervous system or other organs, eg instable coronary heart disease, heart failure, liver failure, kidney failure, hypotension, or history of stroke or myocardial infarction Subject with known coagulation disorders (eg von Willebrand's disease, hemophilia) Subject with known disorders with increased bleeding risk (...) (eg periodontosis, hemorrhoids, acute gastritis, peptic ulcer) Subject with known sensitivity to common causes of bleeding (eg nasal) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02537457 Locations Layout table for location information Japan

2015 Clinical Trials

132. Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects

coagulation disorders (eg von Willebrand's disease, hemophilia) Subject with known disorders with increased bleeding risk (eg periodontosis, hemorrhoids, acute gastritis, peptic ulcer) Subject with known sensitivity to common causes of bleeding (eg nasal) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study

2015 Clinical Trials

133. Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects

(ie, warfarin, low molecular weight heparin, thrombin inhibitors), antiplatelet (eg, clopidogrel), nonsteroidal anti-inflammatory drug, and/or aspirin within 30 days prior to Period 1, Day 1. Subjects with a history of major bleeding or major surgical procedure of any type within 6 months before Period 1, Day 1. Subjects with a history of peptic ulcer, gastrointestinal bleeding including haematemesis, melena, or bleeding from haemorrhoids. Subjects with a history of minor bleeding episodes (...) such as epistaxis, rectal bleeding (spots of blood on toilet paper), or gingival bleeding within 3 months before Period 1, Day 1. Subjects who have any family history, suspected or documented, of coagulopathy or haemoglobinopathy or evidence of abnormal coagulation parameters (eg, PT, INR or aPTT) at Screening. Subjects with an estimated glomerular filtration rate (eGFR) at Screening using the Modification of Diet in Renal Disease (MDRD) equation < 90 mL/min. Likely possibility that the subject

2015 Clinical Trials

134. The Effect of Intra-anal Nifedipine, Used As Add-on to Conservative Therapy, on Pain in Patients With Anal Fissure

of the study Subfissure injection of botulinum toxin in the 3 months prior to screening. Fissure resulting from inflammatory bowel disease, venereal disease, perianal psoriasis, immunodeficiency syndrome Atypical fissure (occurs off the midline) in which secondary causes were not excluded. Deemed by the investigator as anal fissure for which surgery is indicated Anal abscess; Grade 4 hemorrhoids Fixed anal stenosis Active or past history of cardiovascular or cerebrovascular disease including (...) to be clinically significant by the investigator at screening; Has used, in the last two weeks, drugs that may affect blood coagulation, such as Aspirin at a dose higher than 500 mg/day, Warfarin, Sintrom, Enoxaparin, Nadroparin, Heparin, Clopidogrel, Ticlopidine Rivaroxaban, Apixaban, Edoxaban Is treated with drugs that may affect the anal sphincter: Calcium channel blockers such as Nifedipine, Diltiazem or Verapamil Nitroglycerin or nitrates Has, upon physical examination, a rectal deformation or signs

2015 Clinical Trials

135. The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment

of any medication including OTC drugs and herbals within 2 weeks before IMP administration Known coagulation disorders (e.g. haemophilia, von Willebrand´s disease) Known disorders with increased bleeding risk (e.g. peridontosis, haemorrhoids, acute gastritis, peptic ulcer, intestinal ulcer) Known sensitivity to common causes of bleeding (e.g. nasal) History of thromboembolism History of occlusive vascular diseases History of vascular anomalies Impaired liver function (AST, ALT, gGT, bilirubin >2 x

2015 Clinical Trials

136. The University of Wollongong issues a PhD in antivaccine pseudoscience

. At the time, that was a fair defense: Wilyman's personal views shouldn't matter as long as her thesis is held to rigorous academic standards. Knowing what we know now, I have to laugh to keep from crying. In light of Wilyman's thesis being accepted, the reassurances of the University of Wollongong that Wilyman would be held to rigorous standards have been revealed for the humongous pile of fetid dingo's kidneys that they were. Its claim was either a lie or a delusion on the part of the university (...) , a quick shake of the tree dropped an apple in which he didn't even hew to his own stated criteria, and moreover, the example was in his original field. Just to stick with physics (as in the link), MOND has never been mainstream, nor has it been suppressed by some sort of fight-or-flight reaction on the part of journals. Does this de facto make it 'not dissent'? After a while, though, one's choices can coagulate into the equivalent of personal "politics." Indeed, Chris Preston brought up Martin's time

2016 Respectful Insolence

137. The role of endoscopy in patients with anorectal disorders

-WilliamsJ.Longtermreviewofthe results of rubber band ligation of haemorrhoids. Br J Surg 1975;62: 144-6. 76. NeigerA.Hemorrhoidsineverydaypractice.Proctology1979;2:22-8. 77. Zinberg SS, Stern DH, Furman DS, et al. A personal experience in com- paring three nonoperative techniques for treating internal hemor- rhoids.AmJGastroenterol1989;84:488-92. 78. Tanaka S. Cryosurgical treatment of hemorrhoids in Japan. Int Surg 1989;74:146-7. 79. Wright RA, Kranz KR, Kirby SL. A prospective crossover trial of direct current (...) Society for Gastrointestinal Endoscopy (ASGE) 2 guideline and dis- cusses the role of endoscopy in patients with anorectal disorders, including chronic radiation proctopathy, anal ?ssures, internal hemorrhoids and fecal incontinence. Ad- ditional information about the role of endoscopy in the evaluation of patients with perianal disease in in?amma- tory bowel disease is described in another ASGE guideline. 3 CHRONIC RADIATION PROCTOPATHY Among patients receiving prostate irradiation, the rec- tum

2010 American Society for Gastrointestinal Endoscopy

138. Triple vs. Dual Therapy

Non-smoking behaviour Exclusion Criteria: Regular intake of any medication including OTC drugs and herbals within 2 weeks before IMP administration Known coagulation disorders (e.g. haemophilia, von Willebrand´s disease) Known disorders with increased bleeding risk (e.g. peridontitis, haemorrhoids, acute gastritis, peptic ulcer, intestinal ulcer) Known sensitivity to common causes of bleeding (e.g. nasal) History of thromboembolism Anaemia (defined as haemoglobin levels < LLN) Impaired liver (...) and venous thromboembolic prophylaxis due to their underlying co-morbidities. One trial suggests treatment with VKA + clopidogrel without ASA as equal effective as antithrombotic triple therapy (with ASA) in this population. However, the effect in combination with novel oral anticoagulants has not been investigated so far. Study objectives: To evaluate the effect of ticagrelor + apixaban in combination with or without ASA at steady state on markers of coagulation activation and on thrombus size in an ex

2014 Clinical Trials

139. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation]. (Abstract)

in patients (pts) with persistent AF.The analysis included 24 pts (14 females, 10 males) with nonvalvular AF and indications for oral anticoagulant therapy (CHA2DS2-VASc > or = 2, HAS-BLED < 3), hospitalized in the Clinic of Internal Diseases and Clinical Pharmacology of the Medical University of Lodz between July 2012 and September 2013. In the group of patients treated chronically with VKA, laboratory tests (GFR, creatinine, ALT AST, coagulation) were performed during their stay in the clinic (...) observed. After a 6-month therapy, dabigatran prolongs APTT significantly more, as compared to rivaroxaban (p=0.0002). Among patients using dabigatran, 16.7% experienced the following symptoms: abdominal pain, gastritis, nausea. 8.3% patients experienced bleeding from haemorrhoids, easier bruising. In the group of patients receiving rivaroxaban, 16.7% experienced the following symptoms: nosebleeds and easier bruising; 8.3%: bleeding from gums, haematuria. 25%: pruritus, rash: 8.3%. The hazard ratio (HR

2014 Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego Controlled trial quality: uncertain

140. A Trial Comparing the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy

10 after colonoscopy ] Clinically Significant Changes in Vital Signs (Pulse and Blood Pressure) [ Time Frame: From baseline (screening) up to day 10 after colonoscopy (inclusive of assessment at each visit) ] Mean change from baseline to the end-of-trial was observed for pulse and blood pressure (systolic and diastolic). Clinically Significant Changes in Laboratory Values (Haematology, Clinical Chemistry, Coagulation and Urinalysis) [ Time Frame: From baseline (screening) up to day 10 after (...) colonoscopy (inclusive of assessment at each visit) ] Laboratory parameters included routine haematology, clinical chemistry, coagulation and urinalysis. With the exception of urinalysis and urine pregnancy test, which was performed as dip-stick analyses at the trial site, all laboratory tests were analysed by a central laboratory. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>